Walgreens sells shares of drug distributor Cencora
Drugstore chain Walgreens Boots Alliance Inc. (WBA) on Thursday said it had sold shares of drug distributor Cencora Inc. (COR) for approximately $424 million. Walgreens also entered into a share repurchase by Cencora, formerly known as AmerisourceBergen, for proceeds of roughly $250 million. Walgreens said its ownership of Cencora's common stock fell due to the repurchase by Cencora, "but remains at approximately 15%." The drugstore chain said it planned to use the proceeds to repay debt and for general business operations. "The transaction is another decisive action to further simplify the company's portfolio, while improving cash management," Walgreens said, adding that it "remains fully committed to the strategic, mutually beneficial relationship with Cencora," a partner with Walgreens since 2013.
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-09-23 1924ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations